Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 12, Issue 1, 2014, Pages 50-57

  Fan, Katherine Y ^a   Dholakia, Avani S ^a   Wild, Aaron T ^a   Su, Zheng ^b   Hacker Prietz, Amy ^a   Kumar, Rachit ^a   Hodgin, Mary ^a   Hsu, Charles C ^c   Le, Dung T ^a   De Jesus Acosta, Ana ^a   Diaz Jr , Luis A ^a   Laheru, Daniel A ^a   Hruban, Ralph H ^d   Fishman, Elliot K ^d   Brown, Todd D ^d   Pawlik, Timothy M ^a   Wolfgang, Christopher L ^a,e   Tran, Phuoc T ^a   Herman, Joseph M ^a,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BENIGN PANCREATIC DISEASE; CANCER PATIENT; CANCER SIZE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS DISEASE; PROSPECTIVE STUDY;

ADENOCARCINOMA; AGED; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 84893742367     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2014.0006     Document Type: Article

References (30)

1. Green RC Jr, Baggenstoss AH, Sprague RG. Diabetes mellitus in association with primary carcinoma of the pancreas. Diabetes 1958;7:308-311.
2. Chari ST, Leibson VL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504-511.
3. Pannala R, Leirness JB, Bamlet WR, et al. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-987.
4. Aggarwal G, Kamada P, Chari ST. Prevalence of diabetes mellitus in pancreatic cancer compared to common cancers. Pancreas 2013;42:198-201.
5. Hirakawa Y, Ninomiya T, Mukai N, et al. Association between glucose tolerance level and cancer death in a general Japanese population: the Hisayama study. Am J Epidemiol 2012;176:856-864.
6. Qiu H, Wild AT, Wang H, et al. Comparison of conventional and 3-dimensional computed tomography against histopathologic examination in determining pancreatic adenocarcinoma tumor size: implications for radiation therapy planning. Radiother Oncol 2012;104:167-172.
7. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
8. Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 1999;189:1-7.
9. Castellanos EH, Cardin DB, Berlin JD. Treatment of early-stage pancreatic cancer. Oncology (Williston Park) 2011;25:182-189.
10. Lee JH, Kim SA, Park HY, et al. New-onset diabetes patients need pancreatic cancer screening? J Clin Gastroenterol 2012;46:58-61.
11. Schwarts SS, Zeidler A, Moossa AR, et al. A prospective study of glucose tolerance, insulin, C-peptide, and glucagon responses in patients with pancreatic carcinoma. Am J Dig Dis 1978;23:1107-1114.
12. Cersosimo E, Pisters PW, Pesola G, et al. Insulin secretion and action in patients with pancreatic cancer. Cancer 1991;67:486-493.
13. Basso D, Plebani M, Fogar P, et al. Beta-cell function in pancreatic adenocarcinoma. Pancreas 1994;9:332-335.
14. Djiogue S, Nwabo Kamdje AH, Vecchio L, et al. Insulin resistance and cancer: the role of insulin and insulin-like growth factors. Endocr Relat Cancer 2013;20:R1-17.
15. D'Esposito V, Passaretti F, Hammarstedt A, et al. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 2012;55:2811-2822.
16. Mannucci E. Insulin therapy and cancer in type 2 diabetes. ISRN Endocrinol 2012;2012:240634.
17. Wang F, Adrian TE, Westermark G, et al. Dissociated insulin and islet amyloid polypeptide secretion from isolated rat pancreatic islets cocultured with human pancreatic adenocarcinoma cells. Pancreas 1999;18:403-409.
18. Wang F, Larsson J, Abdiu A, et al. Dissociated secretion of islet amyloid polypeptide and insulin in serum-free culture media conditioned by human pancreatic adenocarcinoma cell lines. Int J Pancreatol 1997;21:157-164.
19. Basso D, Millino C, Greco E, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut 2004;53:1159-1166.
20. Basso D, Valerio A, Seraglia R, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas 2002;24:8-14.
21. Valerio A, Basso D, Brigato L, et al. Glucose metabolic alterations in isolated and perfused rat hepatocytes induced by pancreatic cancer conditioned medium: a low molecular weight factor possibly involved. Biochem Biophys Res Commun 1999;257:622-628.
22. Aggarwal G, Ramachandran V, Javeed N, et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in β cells and mice. Gastroenterology 2012;143:1510-1517.
23. Permert J, Ihse I, Jorfeldt L, et al. Pancreatic cancer is associated with impaired glucose metabolism. Eur J Surg 1993;159:101-107.
24. Permert J, Ihse I, Jorfeldt L, et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993;80:1047-1050.
25. Permert J, Adrian TE, Jacobsson P, et al. Is profound peripheral insulin resistance in patients with pancreatic cancer caused by a tumor-associated factor? Am J Surg 1993;165:61-66, discussion 66-67.
26. Permert J, Larsson J, Fruin AB, et al. Islet hormone secretion in pancreatic cancer patients with diabetes. Pancreas 1997;15:60-68.
27. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001;345:1359-1367.
28. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-461.
29. Storey S, Von Ah D. Impact of malglycemia on clinical outcomes in hospitalized patients with cancer: a review of the literature. Oncol Nurs Forum 2012;39:458-465.
30. Decensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3:1451-1461.